GMED insider (Form 144) plans sale of 3,594 common shares

Rhea-AI Filing Summary

GMED insider plans a new stock sale under Rule 144. A person identified in the filing plans to sell 3,594 shares of common stock through Raymond James & Associates on the NYSE, with an indicated aggregate market value of 363,167.00. These shares were acquired from the issuer on 01/08/2026 through a cashless option exercise on the same date. The filing notes that 133,839,166 shares of common stock were outstanding. Over the prior three months, Kyle Kline sold 18,542 common shares on 12/01/2025, generating gross proceeds of 1,667,846.00. The signer represents that they are not aware of undisclosed material adverse information about the issuer.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	RAYMOND JAMES & ASSOCIATES 880 CARILLON PARKWAY ST. PETERSBURG FL 33716	3594	363167.00	133839166	01/08/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/08/2026	CASHLESS OPTION EXERCISE	ISSUER			3594	01/08/2026	CASHLESS EXERCISE

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
KYLE KLINE 15 SOVEREIGN DR DOUGLASSVILLE PA 19518	COMMON	12/01/2025	18542	1667846.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the GMED Form 144 filing disclose?

The Form 144 discloses a planned sale of 3,594 shares of common stock of the issuer on the NYSE through Raymond James & Associates, with an aggregate market value of 363,167.00. The shares were obtained via a cashless option exercise from the issuer on 01/08/2026.

How many GMED shares are planned to be sold and on which exchange?

The filing indicates that 3,594 common shares are to be sold on the NYSE, using Raymond James & Associates as broker.

How were the GMED shares in this Form 144 acquired?

The shares to be sold are common stock acquired from the issuer on 01/08/2026 through a cashless option exercise, with the same date listed as the date of payment and nature of payment noted as cashless exercise.

What past GMED stock sales by this person are disclosed?

The filing reports that Kyle Kline sold 18,542 common shares on 12/01/2025, generating 1,667,846.00 in gross proceeds during the prior three months.

How many GMED shares were outstanding according to this Form 144?

The Form 144 notes that there were 133,839,166 shares of common stock outstanding for the issuer.

What representation does the seller make in the GMED Form 144?

The person for whose account the securities are to be sold represents by signing that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.